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Age-related macular degeneration (AMD) is a leading 
cause of late-onset central vision loss affecting individuals 
over the age of 50 years [1]. The condition has a substantial 
global burden and is expected to affect up to 288 million 
people by the year 2040 [2]. It involves environmental, genetic, 
and physiologic determinants [3] that cause damage to the 
macula, which is an area within the eye required for sharp, 
central vision. Here, the retinal pigment epithelium (RPE) is 
important for maintaining retinal homeostasis by providing 
nutrients and ionic support to the apical photoreceptors 
while facilitating the phagocytic removal of waste products 
and the exchange of biomolecules with the fenestrated 
choroidal capillaries [4]. The basal deposition of drusen, 
which can occur at either the RPE or Bruch’s membrane, can 
significantly affect photoreceptor health [5]. This has been 
previously thought to occur due to the dysregulation of the 
alternative complement pathway, which causes inflammation 
of the RPE. The dysregulation of the alternative complement 
pathway has been shown to be associated with the extensively 
characterized single nucleotide polymorphism (SNP), 
rs1061170, in the Complement Factor H (CFH) gene [6].
The rs1061170 variant is characterized by a cytosine 
nucleotide (C) in place of a thymine nucleotide (T), 
which results in a tyrosine to histidine amino acid residue 
substitution at position 402 (Y402H) in the CFH protein. 
The incidence of the disease associated variant at this locus 
results in a 3.3- to 7.7-fold increase in AMD progression 
for Caucasians homozygous for the risk variant allele, and 
a 2.2- to 4.6-fold increase for heterozygous individuals [6]. 
The amino acid residue substitution principally affects the 
CFH protein, which is a serum glycoprotein responsible 
for attenuating the response of the alternative complement 
pathway by cleaving pro-inflammatory mediators [7, 8]. The 
Y402H allelic variant affects the hydrogen bonding capacity 
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Purpose: To evaluate the efficacy of using a CRISPR/Cas-mediated strategy to correct a common high-risk allele 
that is associated with age-related macular degeneration (AMD; rs1061170; NM_000186.3:c.1204T>C; NP_000177.2:p.
His402Tyr) in the complement factor H (CFH) gene.
Methods: A human embryonic kidney cell line (HEK293A) was engineered to contain the pathogenic risk variant for 
AMD (HEK293A-CFH). Several different base editor constructs (BE3, SaBE3, SaKKH-BE3, VQR-BE3, and Target-
AID) and their respective single-guide RNA (sgRNA) expression cassettes targeting either the pathogenic risk variant 
allele in the CFH locus or the LacZ gene, as a negative control, were evaluated head-to-head for the incidence of 
a cytosine-to-thymine nucleotide correction. The base editor construct that showed appreciable editing activity was 
selected for further assessment in which the base-edited region was subjected to next-generation deep sequencing to 
quantify on-target and off-target editing efficacy.
Results: The tandem use of the Target-AID base editor and its respective sgRNA demonstrated a base editing efficiency 
of facilitating a cytosine-to-thymine nucleotide correction in 21.5% of the total sequencing reads. Additionally, the 
incidence of insertions and deletions (indels) was detected in only 0.15% of the sequencing reads with virtually no off-
target effects evident across the top 11 predicted off-target sites containing at least one cytosine in the activity window 
(n = 3, pooled amplicons).
Conclusions: CRISPR-mediated base editing can be used to facilitate a permanent and stably inherited cytosine-to-
thymine nucleotide correction of the rs1061170 SNP in the CFH gene with minimal off-target effects.
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of the CFH protein and impairs its ability to dock to the 
appropriate receptor on the RPE or Bruch’s membrane [9, 
10]. This stereochemical impairment results in an increase 
in the fraction of uncleaved pro-inflammatory cytokines and 
causes inflammation of the RPE.
The discovery of an adaptive prokaryotic immune system 
that requires the use of only a single endonuclease (Cas9) 
to mediate a DNA double-strand break (DSB) [11], allowed 
for the development of a programmable nuclease that could 
target DNA in a site-specific manner [12]. Here, the single-
guide RNA (sgRNA) component of the CRISPR/Cas9 system 
facilitates targeted DNA editing at a user-defined nucleotide 
sequence [12, 13]. The binding between the Cas9 protein and 
the target DNA strand is dictated by its protospacer-adjacent 
motif (PAM) site, which is a short consensus sequence of 
nucleotides that occur adjacent to the target DNA sequence 
[12, 14].
Herein, we describe the application of a modified 
Clustered Regularly Interspersed Short Palindromic Repeats/
CRISPR associated protein 9 (CRISPR/Cas9) system, 
known as ‘base editing’ [15], to mediate a precise single 
nucleotide change targeting the AMD-associated risk allele 
at the rs1061170 locus. Base editing mitigates the previously 
characterized risks associated with introducing DSBs into the 
genome, which can lead to imprecise insertions and deletions 
(indels) [16, 17]. Further, base editing has a dramatically 
higher editing efficiency compared to homology-directed 
repair (HDR), a process that has a notoriously low efficiency 
in somatic cells due to the competing DNA repair pathway 
of non-homologous end joining (NHEJ), where nucleotide 
insertions and deletions are typically generated [18, 19].
The CRISPR-mediated base editor fuses a cytidine 
deaminase, such as APOBEC3 [20], APOBEC1 [15], or 
human-AID (activation-induced cytidine deaminase) [21, 22], 
to a modified Cas9 protein to allow for site-directed cytosine-
to-thymine nucleotide corrections [23]. Its nickase mechanism 
and the fusion of a uracil DNA glycosylase inhibitor (UGI) 
allows the introduction of a nucleotide correction in a stably 
inherited manner in both dividing and non-dividing cells 
[12, 24]. Although there are several variants of base editors 
currently available [20, 25], we selected and screened for the 
most well characterized variants of base editors. CRISPR/
Cas base editors targeting the disease-relevant locus were 
screened due to their varying PAM requirements, sgRNA 
target sequence, and anticipated activity window. As such, 
base editing variants with the same mutagenicity profiles 
were selected to observe if the sequence-specific context 
of the locus has any bearing on the efficacy of the targeted 
correction (BE3, SaKKH-BE3, SaBE3, and VQR-BE3) [25]. 
Here, the PAM variant base editors (SaKKH-BE3, SaBE3, 
and VQR-BE3) share the same structural arrangement of BE3 
in terms of the choice of the deaminating protein (APOBEC3), 
linker length, and terminal protein fusions, but markedly 
differ in the range of PAM targetable DNA substrates given 
their variations in the Cas9 protein component. Further, to 
profile the effects of the activity window on correcting the 
rs1061170 SNP, a base editor with a different architecture and 
activity window (Target-AID) was evaluated [26]. While the 
respective PmCDA1 and APOBEC3 proteins of Target-AID 
and BE3 both fulfill a deaminating role, each protein 
possesses a differing mutagenicity profile and processive 
capability [27-30]. These differences in protein function 
require much-needed consideration and clarification for use 
in the mostly cytosine-deplete sequence space surrounding 
the rs1061170 SNP. After the initial screening of base editors 
at the Y402H CFH locus, we selected the most active base 
editor for further off-target assays to explore its therapeutic 
potential.
METHODS
Generation of a HEK293A-CFH(p.His402) fragment cell 
line: To evaluate the efficacy of base editing to correct the 
AMD-associated rs1061170 variant, a commercial human 
embryonic kidney cell line (HEK293A; Invitrogen, CA) was 
engineered to contain the pathogenic risk variant by using 
a lentiviral method to knock-in a gene fragment containing 
exon 9 of the CFH gene. Briefly, the pLenti.AS2.Luci.puro 
vector (RNAiCore; Academia Sinica, Taipei, Taiwan) was 
digested using NheI and EcoRI (New England Biolabs, 
MA) to insert the synthetic CFH gene fragment (gBlock 
gene fragment, Integrated DNA Technologies, IA). Cell line 
authentication was performed using short tandem repeat 
DNA profiling with the following markers: AMEL, CSF1PO, 
D5S818, D7S820, D13S317, D16S539, D21S11, TH01, TPOX, 
and vWA through the Australian Genome Research Facility 
LTD, VIC, Australia (Appendix 1, Appendix 2, and Appendix 
3). Cell line transduction and ongoing cell culture conditions 
were followed as previously described [31].
Modification of SpCas9 sgRNA scaffold: CHOPCHOP was 
used to evaluate the incidence of internal RNA interactions 
between the protospacer portion of the sgRNA and the 
sgRNA scaffold backbone [32]. The webtool RNAfold 
[33] was used to investigate the folding spontaneity of the 
unmodified and modified SpCas9 sgRNA scaffolds. The 
following scaffold modifications were considered: a canonical 
A54:U60 substitution in the critical stem loop one region and 
a modified stem loop two and three linker region, and an A:U 
nucleobase pair flip at U25 in the repeat:anti-repeat duplex of 
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the sgRNA scaffold [34] and an extension of the repeat:anti-
repeat duplex (F-E modified scaffold; Appendix 2). Each 
modified scaffold contained a 5′ spacer portion specific for 
rs1061170 and a GGG PAM site, and a 3′ scaffold backbone 
(sgRNA2 and sgRNA2G, Appendix 2). The modified 
scaffolds were prepared according to the gBlocks® Gene 
Fragments (Integrated DNA Technologies, IA) protocols as 
described above.
CRISPR-base editing constructs and sgRNA cassette 
generation: The Target-AID construct was assembled 
using the HiFi DNA Assembly method (New England 
Biolabs, MA) where the Target-AID was subcloned from the 
pcDNA3.1_pCMV-nCas-PmCDA1-ugi pH1-gRNA (HPRT) 
plasmid (5,365 base pairs; Addgene plasmid #79620); the 
P2A-fragment and Blasticidin resistance gene were amplified 
from the LentiCas9-BLAST plasmid (Addgene Plasmid 
#52962); the vector backbone was amplified from pCMV-BE3 
(3,361 base pairs; Addgene plasmid #73021). The individual 
PCR fragments of the construct were amplified using the 
Q5 High-Fidelity DNA polymerase (New England Biolabs) 
and purified using the QIAquick® PCR Purification Kit 
(QIAGEN, Hilden, Germany) according to the manufacturer’s 
instructions. NEB® Stable Competent E. coli (New England 
Biolabs) was used for transformation following standard 
transformation protocol. Plasmid DNA was harvested using 
the Wizard® Plus SV Minipreps DNA Purification Systems 
(Promega Corporation, WI) according to the manufacturer’s 
instructions.
For the U6-promoter driven expression of sgRNAs for 
the SaCas9 PAM variants, SaBE3 (Addgene Plasmid #85169) 
and SaKKH-BE3 (Addgene Plasmid #85170), CFH-locus 
specific sgRNAs (Appendix 2) were annealed and cloned 
into the digested px552-CMV-U6-SaCas9 (Addgene Plasmid 
#107053) construct at the SapI site. Whereas the cloning 
of SpCas9-specific sgRNA for the SpCas9 PAM variant, 
VQR-BE3 (Addgene Plasmid #85171) and sgRNA oligos 
(Appendix 2) were annealed and cloned into the px552-CMV-
mCherry-U6-SpCas9 sgRNA scaffold (Addgene Plasmid 
#60958). Constructs were transformed into NEB® Stable 
Competent E. coli (New England Biolabs) and plasmid DNA 
was harvested using the Wizard® Plus SV Minipreps DNA 
Purification Systems (Promega).
HEK293A-CFH(p.His402) fragment cell line transfection 
with CRISPR/sgRNA constructs and cassettes: HEK293A-
CFH(p.His402) fragment cells were plated to a final density 
of 75,000 cells per well in a 12-well plate. After one day of 
incubation at 37 °C and 5% CO2, the confluency of the cells 
was checked to ensure it was between 40% and 70%. Then, 
500 ul of 10% fetal bovine serum (FBS) media (Thermo Fisher 
Scientific™, MA) was replaced and the DNA:nanoparticle 
complex was prepared following the manufacturer's protocol. 
For each condition, an aliquot containing 450 ng of sgRNA 
scaffold (gBlocks® Gene Fragments) or 1 µg of px552-CMV-
mCherry-U6-SaCas9 or SpCas9 sgRNA scaffold (Appendix 
2), and 1 µg of the CRISPR/Cas9 plasmid were prepared in 
46 µl of Opti-MEM (Thermo Fisher Scientific™). Then, 
3.5 µl of FuGENE® HD (Promega) was added, followed 
by pulse spin and vortex. The reaction aliquot was then 
incubated for 10 min at room temperature before adding it 
in a dropwise manner to each well of the 12-well plate. The 
HEK293A-CFH(p.His402) fragment cells were incubated at 
37 °C for three days.
Following transfection of the HEK293A-CFH(p.His402) 
fragment cells with the CRISPR and sgRNA constructs, 
20 µg/ml of blasticidin was added one day after transfection 
for a six-day (blasticidin) selection of the cells. Genomic DNA 
was harvested using the QIAamp DNA minikit (QIAGEN) 
from enriched cells, six days after transfection. Amplification 
of the exogenous CFH fragment tag was performed using 
KOD DNA polymerase (Merck Millipore, Darmstadt, 
Germany) with the Myc and FLAG tag primers (Appendix 
2) and PCR products were purified using the Wizard® SV 
Gel and PCR Clean-Up System (Promega, WI). PCR samples 
were sent for Sanger sequencing with the Myc tag primer.
High-throughput next generation deep sequencing of base-
edited gDNA samples: Nested PCR amplification reactions 
were performed on the extracted gel-purified PCR amplicons 
for the on-target base edited cells following transfection 
using custom primers annealing to the CFH gene fragment 
and a compatible overhang for Illumina forward and reverse 
adapters (Appendix 2). For the off-target assays, the top 
20 scoring sgRNAs were selected using CHOPCHOP 
[32]. The sgRNAs were then further evaluated using the 
following criteria: a cytosine occurs within a −1 to +5 
nucleotide position within the 20 nucleotide protospacer, 
whereby the PAM consensus sequence is in position +21 
to +23; a compatible NGG-style PAM site must flank the 
20-nucleotide protospacer; the sgRNA protospacer for the 
off-target site must contain no more than three mismatches 
compared to the on-target sgRNA sequence. Briefly, using 
standard conditions for Q5 High-Fidelity DNA polymerase 
(New England Biolabs), the on-target PCR amplicons were 
amplified using the following thermocycling conditions: 
initial denaturation at 98 °C for 30 s, cycling at 98 °C for 10 
s, 60 °C for 10 s, 72 °C for 15 s, and a final extension of 72 °C 
for 2 min. Off-target sites were PCR-amplified using the 
extracted gDNA sample directly after transfection on both the 
LacZ-treated negative control and on the base editor-treated 
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gDNA samples using the previously described thermocycling 
conditions. A secondary PCR reaction was performed on 
the resultant PCR amplicons following validation of the 
correct size using the gel purification method as previously 
described. Briefly, the Nextera™ DNA CD Indexes (24 
Indexes, 24 Samples; Illumina, Inc., San Diego, CA) was used 
to barcode the previously tagged PCR amplicons containing 
the Illumina adaptor overhangs. The LacZ-negative control 
treated or base-edited samples each have, respectively, one 
on-target PCR amplicon and 11 off-target PCR amplicons. 
The base-edited or LacZ-negative control PCR amplicons 
were each barcoded individually according to a secondary 
PCR reaction (Appendix 3) [35]. The resultant PCR amplicon 
library was then quantified using Qubit measurement and 
normalized to 4 nM before being pooled into a single tube 
for next generation deep sequencing using the MiSeq Reagent 
Kits v2 (500-cycles; Illumina, Inc. CA). The matlab script, 
which was adapted from Gaudelli and colleagues [35], was 
used for determining the incidence of cytosine-to-thymine 
nucleotide changes in either the on-target treated sample 
or the off-target sites, relative to the LacZ negative control 
(Appendix 3).
RESULTS
Base editor constructs (BE3, Target-AID, SaBE3, 
SaKKH-BE3, and VQR-BE3) were co-transfected with 
their respective sgRNA expressing cassettes targeting the 
rs1061170 locus in the HEK293A-CFH(p.His402) fragment 
cell line (Figure 1). No base editing was observed on direct 
Sanger sequencing with the BE3, SaBE3, SaKKH-BE3, or 
VQR-BE3 constructs, whereas appreciable cytosine-to-
thymine editing was observed with the Target-AID construct 
(Figure 2A; n = 3).
Next-generation deep sequencing was performed on the 
Target-AID base-edited cells. The median number of reads 
was 53,631 across the on-target and putative off-target loci 
(ranging from 569 to 430,308 reads). The overall editing 
efficiency showed that a cytosine-to-thymine nucleotide 
conversion occurred in 21.5% of the total sequencing reads 
at the target risk allele (pooled amplicons, n = 3). Nucleotide 
product purity for the base edited locus also revealed no 
unexpected nucleotide transitions or transversions beyond 
that of the intended C:G to T:A nucleotide transition (Figure 
2B). The target protospacer revealed a minimal incidence of a 
G:C to A:T nucleotide transition at the G8 nucleotide. Further, 
the incidence of indel formation at the target region was also 
evaluated and revealed an indel formation frequency of only 
0.15%.
Figure 1. Activity of different base editors targeting the rs1061170 SNP. The base editor variant, sgRNA protospacer and PAM consensus 
nucleotide, and incidence of base editing are indicated. Base editing was determined if a peak was observed at the risk variant allele following 
analysis of Sanger sequencing chromatograms compared to the LacZ negative control (n = 3 biologic replicates performed on different days 
for all base editor constructs). PAM sequences and gRNA target sequences are shown in orange and blue, respectively. Putative base editor 
activity windows are displayed in green, where dark green indicates higher editing efficiency and light green denotes lower editing efficiency.
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To investigate the incidence of unintended off-target 
effects, the top 11 putative off-target sites were profiled. 
Off-target sites were selected based on the criteria of one-to-
three nucleotide mismatches occurring within the sgRNA 
protospacer relative to the target locus sgRNA, and the 
incidence of at least one cytosine nucleotide occurring within 
the expected −1 to 5 nucleotide window of the sequence space 
flanked by an NGG-compatible PAM consensus sequence. 
Next-generation deep sequencing showed no detectable 
off-target effects at any of the nucleotide positions within the 
profiled protospacer sequence and their surrounding regions 
(Figure 2C).
Using the HEK293A-CFH(p.His402) fragment cells, we 
also investigated the utility of a SpCas9 scaffold enhancement. 
Cotransfection of a plasmid expressing SpCas9 and a sgRNA 
targeting the rs1061170 SNP demonstrated clear evidence of 
Figure 2. Editing efficiency of the Target-AID base editor at Y402H CFH variant (rs1061170). A: Sanger sequencing chromatograms showing 
the target locus. Control refers to HEK293A-CFH(p.His402) cells that have been treated with a combination of the Target-AID base editor 
with a sgRNA targeting LacZ. The second chromatogram displays results following transfection with the Target-AID base editor and a 
sgRNA specific to the rs1061170 region. The highlighted region is the putative activity window of Target-AID showing the incidence of a 
C:G to T:A nucleotide correction. B: Base calling for targeted next-generation deep sequencing of the base-editor treated HEK293A-CFH(p.
His402) cells. Percentages represent the fraction of sequencing reads occupied by a particular nucleotide at the specified position. The target 
protospacer is highlighted in red and each nucleotide is numbered 1 to 20 in which the PAM consensus sequence is considered positions 
+21 to +23. Deep sequencing shows that 21.5% of the target cytosines were edited into thymine nucleotides at position C1. Additionally, the 
percentage of indel formation is 0.15% (amplicon results of three independent biologic replicates). C: List of sgRNA sequences screened at 
the top 11 off-target sites that also contain at least one cytosine in the putative Target-AID activity window in the presence of a NGG PAM 
site. Each off-target site was evaluated using next generation deep sequencing and no off-target base editing was identified.
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indel formation occurring three nucleotides upstream from 
the GGG PAM site (n = 3). Incidence of the neighboring 
AGG PAM motif (n = 3, data not shown) showed poor indel 
formation at this nucleotide sequence, suggesting poor 
Cas9:sgRNA localization. In an attempt to further optimize 
the editing efficiency of the CRISPR/Cas9 platform, the 
sgRNA component was altered with key modifications aimed 
at increasing the stability of Cas9:sgRNA complexation. We 
evaluated the effects of reducing the linker length between 
critical stem loop regions of the sgRNA scaffold (stem 
loops one and two), extending the repeat:anti-repeat duplex 
of the scaffold, introducing key nucleotide substitutions in 
the sequence space following the sgRNA protospacer to 
remove a putative transcription stop signal from within the 
sgRNA scaffold, and introducing a stabilizing nucleotide 
substitution into stem loop one to reduce the incidence of 
strong interactions adversely affecting sgRNA folding. 
Despite these modifications, the overall effects of modifying 
the sgRNA scaffold were negligible when compared to 
either the original sgRNA scaffold or the modified variant 
with the extended repeat:anti-repeat duplex. Overall cutting 
efficiency indicating Cas9:sgRNA localization did not show 
further improvements than what had already been observed 
(Appendix 2).
DISCUSSION
This proof-of-concept work demonstrates the feasibility of 
targeting the AMD-associated high Y402H CFH risk-variant 
cytosine by facilitating a cytosine-to-thymine (or guanine-to-
adenine) nucleotide transition. We observed that base editing 
occurs in a remarkably precise manner in which only a single 
nucleotide correction is seen at the target cytosine, with no 
significant off-target deamination event occurring outside 
the sequence space of rs1061170. Given the characteristically 
low incidence of cytosines occurring within the proximal 
sequence space, the resultant deamination event is highly 
localized. Additionally, there were virtually no detectable 
off-target deamination events observed at the top eleven 
off-target sites and no appreciable indel formation was 
observed despite the use of a nickase variant of SpCas9.
Our work extensively explored the immediate sequence 
space of the rs1061170 SNP by evaluating the incidence of base 
editing with a plethora of PAM-diverse base editor variants 
and their respective sgRNAs. It is tempting to consider the 
four-to-five nucleotide activity window of the base editor 
as generous when the target is only a single nucleotide. 
Nonetheless, the task of selecting the most appropriate base 
editor can be frustrated by the spatially exhaustive exercise of 
re-orientating the sgRNA, the sense strand, and the antisense 
strand. For example, additional parameters require careful 
consideration, such as the restrictive PAM site requirements, 
the apparent activity bias of some sgRNAs sequences, and 
the incidence of unintended amino acid residue substitutions 
in the surrounding sequence space. Here, base editing was 
only observed with the pairing between the Target-AID base 
editor construct and its respective sgRNA. No base editing 
was observed with other constructs despite the target cytosine 
occurring in several putative base editor activity windows 
(Figure 1). This finding is likely attributable to the fact 
that the optimal activity window varies across the putative 
window and is specific to each protospacer sequence and base 
editor construct [36]. For example, in a 20-nucleotide spacer, 
no run-off base editing at the C1 position was observed from 
the activity of BE3, which has a maximal activity window 
positioned between four and eight nucleotides wherein the 
PAM consensus sequence is considered to be positions 21 
to 23 nucleotides. This observation strongly highlights the 
importance of overlapping the suggested, putative activity 
window of the base editor construct with its target cytosine. 
Although, the use of other PAM-relaxed Cas9 orthologs, such 
as the recently developed xCas9 or SpCas9-NG, may appear 
attractive, it was noted that a significant proportion of the 
introduced mutations, whether through random mutagenesis 
in the case of xCas9 or the rational design for SpCas9-NG, 
appeared to affect the on-target base editing efficiency of 
these variants at the NGG PAM sites [37, 38]. Nonetheless, 
other factors such as the sequence-specific nucleotide context 
of each sgRNA may also be a prevailing factor in determining 
base editing efficiency.
We evaluated two neighboring SpCas9 sgRNAs 
corresponding to a GGG and an AGG PAM sequence (Figure 
1) and found poorer indel formation with the AGG (n = 3, 
data not shown) PAM consensus sequence relative to the 
GGG PAM motif, which was an observation that mirrored 
the apparent partiality of some nucleotide sequences for 
Cas9:sgRNA localization and activation [39, 40]. Chadwick 
and colleagues tested over 30 different sgRNAs but found 
that only 12 were amenable to base editing at their assayed 
locus [41]. Although we attempted to address the potential 
incidence of misfolded sgRNA scaffolds by introducing key 
mutations aimed at reducing internal RNA interactions and 
interruptions to structurally significant motifs within the 
scaffold, we observed no further increase in Cas9 activity 
than what was already evident with either the original 
scaffold or the F-E modified variant [42]. Prior to evaluating 
the incidence of base editing, each sgRNA sequence was 
ranked algorithmically and their scores suggested appreciable 
activity at the suggested sites, which we initially confirmed 
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by observing the frequency of indel formation at the loci [40, 
43].
Future directions for this work would be to evaluate the 
changes in the serum levels of oxidative stress biomarkers in 
an in vivo system with a risk-variant encoded CFH protein 
profile against that of the corrected variant. Promising 
human-chimeric mice models have shown that some 
functional, photoreceptor rescue was possible when the risk 
variant allele was replaced with its non-risk variant form 
[44]. Other mouse models have further elucidated the in vivo 
mechanistic consequences of the Y402H mutation and its 
role in increasing the serum biomarkers for oxidative stress 
[44, 45]. Therefore, it would be reasonable to suggest that the 
use of the Target-AID base editor with its respective sgRNA 
could provide scope for measuring the in vivo recovery of 
photoreceptor activity.
In conclusion, we demonstrated the feasibility of using 
a cutting-free and potentially indel-free approach toward 
facilitating gene-based anticipatory therapy for a common 
high-risk variant that is found to be strongly associated with 
AMD. Appreciable base editing efficiencies were noted 
at the target loci in a highly precise manner with virtually 
no observed off-target events or indel formation. Here, the 
feasibility of base editing on one of the most significant risk 
factors for AMD progression has significant implications for 
the development of a potential, single-dose injectable therapy 
targeting dysregulated RPE cells and reducing the systemic 
contribution of cleavage-incompetent CFH proteins produced 
by the liver [49], if administered to the liver and the RPE 
using DNA-free approaches [50].
APPENDIX 1. MODIFICATION OF THE SGRNA 
SCAFFOLD BACKBONE REVEALS NEGLIGIBLE 
MUTATOR EFFECTS ON THE FREQUENCY OF 
INDEL FORMATION.
(A) A schematic overview of the sgRNA scaffold. The linker 
between stem loops one and two was truncated to a single U 
nucleotide, whereas the incidence of strong internal gRNA 
interactions within stem loop 1 was abrogated by introducing 
a canonical A54:U60 nucleotide substitution. The combination 
of these two mutations show robust tolerance for the scaffold 
to be modified. The F-E modified scaffold (d) comprising an 
extended repeat:anti-repeat region and tetraloop also shows 
comparable effects on indel formation frequency [42]. (B) The 
frequency of indel formation following the introduction of 
these mutations shows a negligible mutator effect. To access 
the data, click or select the words “Appendix 1.”
APPENDIX 2.
Oligonucleotide primer and gBlocks Gene Fragments 
sequences and used for the construction and sequencing 
of constructs. To access the data, click or select the words 
“Appendix 2.”
APPENDIX 3.
Twelve pairs of CFH-specific primers containing Illumina 
adapters were used to subject base-edited and LacZ-negative 
control treated gDNA samples to next generation deep 
sequencing. The chromosomal position and the reference 
nucleotide sequence for the Matlab base calling script is 
displayed [35]. To access the data, click or select the words 
“Appendix 3.”
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